

Microsoft Bing

国内版 国际版

Diagnostic usefulness of selected proteases and acute phase factor

Sign in

ALL IMAGES VIDEOS

179,000 Results Any time ▾

Novel diagnostics for aggravating pancreatic fistulas at ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093703>

Jul 14, 2014 · Core tip: The diagnostic performance of inflammatory markers and amylase content in drain fluid were compared to identify sensitive predictors of clinically relevant postoperative pancreatic fistulas (POPFs) at the acute phase after pancreatectomy. Receiver operating characteristic curve analyses revealed that the changes in C-reactive protein (CRP) levels from postoperative day (POD) 1 ...

Cited by: 27 Author: Mitsuro Kanda, Tsutomu Fujii, Hidaki Tak...

Publish Year: 2014

Prognostic Factors for Patients With Advanced Colorectal ...

<https://clinicaltrials.gov/ct2/show/NCT01068132>

Feb 12, 2010 · Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

Search Tools

Turn off Hover Translation (关闭取词)

ALL

IMAGES

VIDEOS

59,200 Results

Any time ▾

Plasma clusterin as a candidate pre-diagnosis marker of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334607>

Feb 14, 2015 · Methods. After an exploratory study on the comprehensive plasma proteome analysis by liquid chromatography-tandem mass spectrometry from ten **colorectal** cancer cases enrolled at **diagnosis**, and ten matched controls (**Phase 1**), a similar preliminary study was performed on prospective plasma samples from ten **colorectal** cancer cases, enrolled years before disease development, and ten ...

Cited by: 20

Author: Michela Bertuzzi, Cristina Marelli, Renzo Ba...

Publish Year: 2015

Study of Pembrolizumab, Binimetinib, and Bevacizumab in ...

<https://clinicaltrials.gov/ct2/show/NCT03475004> ▾

Mar 23, 2018 · This is an open-label, single-center, single-arm **phase II** clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic **colorectal adenocarcinoma** who have not responded to prior therapy.

Allocation: Randomized

Estimated Enrollment : 40 participants

Intervention Model: Single Group Assignment

Study Type : Interventional (Clinical Trial)

Current status and prospects of clinical proteomics ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125662>

Nov 07, 2006 · The study consisted of a training set of samples from 40 patients with **colorectal** cancer (all Dukes' D) and 49 healthy controls. The second set included samples from 37 patients with **colorectal** cancer (1 Dukes' A, 2 Dukes' B, 12 Dukes' C, 17 Dukes' D, 5 unknown) and 31 healthy controls.

Cited by: 60

Author: M E de Noo, R A E M Tollenaar, A M Deelder...

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 66420

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Diagnostic usefulness of selected proteases and acute phase factors in patients with colorectal adenocarcinoma.

Proteases usefulness in colorectal adenocarcinoma diagnosis

Abstract

BACKGROUND

Uncontrolled growth and loss of control over basic metabolic functions, leading to invasive proliferation and metastases, are the salient traits of malignant tumours in general and colorectal cancer in particular. Invasion and metastases hinder effective tumour treatment. While surgical techniques and radiotherapy can be used to remove tumour focus, only chemotherapy can eliminate dispersed neoplastic cells. However

Match Overview

1

Internet 33 words
on wikipedia.org

1%

国内版

国际版

Diagnostic usefulness of selected proteases and acute phase factor



ALL

IMAGES

VIDEOS

59,800 Results

Any time ▾

Study of Pembrolizumab, Binimetinib, and Bevacizumab in ...

<https://clinicaltrials.gov/ct2/show/NCT03475004> ▾

Mar 23, 2018 · This is an open-label, single-center, single-arm phase II clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic colorectal adenocarcinoma who have not responded to prior therapy.

Allocation: Randomized

Estimated Enrollment : 40 participants

Intervention Model: Single Group Assignment

Study Type : Interventional (Clinical Trial)

Current status and prospects of clinical proteomics ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125662>

Nov 07, 2006 · The study consisted of a training set of samples from 40 patients with colorectal cancer (all Dukes' D) and 49 healthy controls. The second set included samples from 37 patients with colorectal cancer (1 Dukes' A, 2 Dukes' B, 12 Dukes' C, 17 ...

Cited by: 60

Author: M E de Noo, R A E M Tollenaar, A M Dee...

Publish Year: 2006

High expression of RRM2 as an independent predictive ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906179>

Feb 15, 2021 · High expression of RRM2 is an independent risk factor for overall survival. Kaplan-Meier survival analysis showed that high RRM2 expression was associated with poor prognosis ($p = 7.86 \times 10^{-4}$), as shown in Figure 3A. Subgroup analysis by different clinical features demonstrated that high RRM2 expression was significantly associated with poor prognosis in LUAD cases more than 65 years old ($p \dots$

Author: Cheng-Yu Jin, Liang Du, A-Han Nuerla... Publish Year: 2021

Plasma clusterin as a candidate pre-diagnosis marker of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334607>

Feb 14, 2015 · Methods. After an exploratory study on the comprehensive plasma proteome analysis by liquid chromatography-tandem mass spectrometry from ten colorectal cancer cases enrolled at diagnosis, and ten matched controls (Phase 1), a similar preliminary study was performed on prospective plasma samples from ten colorectal cancer cases, enrolled years before disease ...

Cited by: 20

Author: Michela Bertuzzi, Cristina Marelli, Renzo ...

Publish Year: 2015